ReviewCancer2014
Medical management of metastatic medullary thyroid cancer.
Review in Cancer, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 47 citations in OpenAlex.
- Machine-learning prediction of 3- and 5-year mortality in lymph-node-positive medullary thyroid carcinoma: a study based on the SEER database and external validation in a Chinese cohort.Frontiers in oncology · 2026Article
- Patient-derived medullary thyroid cancer organoids: a potential model for mechanistic studies on diagnostics and therapy.European thyroid journal · 2025Article
- Limited Thyroidectomy Achieves Equivalent Survival to Total Thyroidectomy for Early Localized Medullary Thyroid Cancer.Cancers · 2024Article
- Molecular genetics, therapeutics and RET inhibitor resistance for medullary thyroid carcinoma and future perspectives.Cell communication and signaling : CCS · 2024Review
- Expression and prognosis analysis of integrin subunit α3 (ITGA3) in papillary thyroid cancer.Heliyon · 2024Article
- LIBRETTO-531: a phase III study of selpercatinib in multikinase inhibitor-naïveFuture oncology (London, England) · 2022Article
- Review
- Successful Treatment with Selpercatinib for Ectopic Cushing's Syndrome Due to Medullary Thyroid Cancer.Current oncology (Toronto, Ont.) · 2022Article
- A Retrospective Study of Serum Calcium Status in Tehran, Iran (105,128 Samples, from 2009-2018).Iranian journal of public health · 2022Article
- Stereotactic radiotherapy is a useful treatment option for patients with medullary thyroid cancer.BMC endocrine disorders · 2021Article
- Article
- Emerging Roles of Circular RNAs in Thyroid Cancer.Frontiers in cell and developmental biology · 2021Review
- Silencing of zinc finger protein 703 inhibits medullary thyroid carcinoma cell proliferationOncology letters · 2020Article
- The role of postoperative adjuvant radiotherapy in the local control in medullary thyroid carcinoma.Endocrine connections · 2020Article
- Leveraging Atropisomerism to Obtain a Selective Inhibitor of RET Kinase with Secondary Activities toward EGFR Mutants.ACS chemical biology · 2019Article
- Therapeutic effects of adenovirus-mediated CD and NIS expression combined with NaOncology letters · 2017Article
- Uncommon response of cisplatin and etoposide for treatment of advanced medullary thyroid carcinoma.Clinical case reports · 2017Article
- Selective Ablation of Tumor Suppressors in Parafollicular C Cells Elicits Medullary Thyroid Carcinoma.The Journal of biological chemistry · 2017Article
- MiR-182 promotes cancer invasion by linking RET oncogene activated NF-κB to loss of the HES1/Notch1 regulatory circuit.Molecular cancer · 2017Article
- Targeted Therapy for Medullary Thyroid Cancer: A Review.Frontiers in oncology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Medullary thyroid cancer (MTC) is an aggressive form of thyroid cancer that occurs in both heritable and sporadic forms. Discovery that mutations in the rearranged during transfection (RET) proto-oncogene predispose to familial cases of this disease has allowed for presymptomatic identification of gene carriers and prophylactic surgery to improve the prognosis of these patients. A significant number of patients with the sporadic type of MTC and even those with familial disease still present with lymph node or distant metastases, making surgical cure difficult. Over the past several decades, many different types of therapy for metastatic disease have been attempted with limited success. Improved understanding of the molecular defects and pathways involved in both familial and sporadic MTC has resulted in new hope for these patients with the development of drugs targeting the specific alterations responsible. This new era of targeted therapy with kinase inhibitors represents a significant step forward from previous trials of chemotherapy, radiotherapy, and hormone therapy. Although much progress has been made, additional agents and strategies are needed to achieve durable, long-term responses in patients with metastatic MTC. This article reviews the history and results of medical management for metastatic MTC from the early 1970s up until the present day.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.